PGRN was measured on all subjects, whereas IL-6 measures were performed on all except 2 of the FTLD patients, all except 2 of the AD patients and all except 3 of the control subjects, where insufficient sample remained to complete both assays. The gene discussed is IL6; the disease is Alzheimer disease.